Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma
NCT00712062
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Lack of accrual
Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG:
Pemetrexed
Sponsor
University of Florida